Department of Energy, Shine Working on $263M Deal to Establish Mo-99 Supply in US

Why It Matters

A secure, home‑grown Mo‑99 supply strengthens the U.S. healthcare supply chain and reduces vulnerability to foreign reactor shutdowns, while advancing commercial fusion applications.

Key Takeaways

• DOE offers up to $263 M loan to Shine for Mo‑99 production
• Chrysalis will be the world’s largest medical isotope facility
• Fusion‑based process uses recycled liquid uranium, cutting waste
• Domestic Mo‑99 supply reduces reliance on aging foreign reactors
• Millions of diagnostic doses per year expected once Chrysalis operates

Pulse Analysis

Molybdenum‑99 is the backbone of nuclear medicine, powering technetium‑99m generators that enable imaging for cancer, cardiac, and orthopedic diagnostics. The United States imports more than 90% of its Mo‑99 from a handful of aging reactors in Europe and Canada, creating a fragile supply chain vulnerable to maintenance outages and geopolitical shifts. Recent shortages have prompted hospitals to delay procedures, highlighting the strategic importance of a reliable domestic source.

Shine Technologies’ Chrysalis project leverages a novel fusion‑driven approach that bombards a liquid uranium target, then recycles the material to generate Mo‑99. This method dramatically reduces radioactive waste compared with traditional fission reactors and promises lower production costs. The DOE’s conditional $263 million financing underscores federal confidence in commercial fusion as a viable energy and medical solution. By meeting technical, environmental, and financial milestones, Shine could unlock the first large‑scale, U.S.-based isotope supply, positioning the company at the intersection of advanced nuclear technology and healthcare.

The broader implications extend beyond radiology labs. A stable Mo‑99 supply enhances patient access to timely diagnoses, potentially improving outcomes and lowering overall healthcare expenditures. It also signals a shift toward domestic nuclear manufacturing, aligning with national security objectives and the Biden administration’s clean energy agenda. As the industry watches, successful deployment of Chrysalis could spur further investment in fusion‑based medical applications, catalyzing a new era of low‑carbon, high‑value nuclear products.